scholarly journals Differential prognostic factors in low‐ and high‐burden de novo metastatic hormone‐sensitive prostate cancer patients

2020 ◽  
Author(s):  
Masaki Shiota ◽  
Naoki Terada ◽  
Toshihiro Saito ◽  
Akira Yokomizo ◽  
Naoki Kohei ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
De Novo ◽  
High Burden ◽  
Hormone Sensitive

scholarly journals Prognostic Factors in Hormone-sensitive Prostate Cancer Patients Treated With Combined Androgen Blockade: A Consecutive 15-year Study at a Single Japanese Institute

In Vivo ◽  
2021 ◽  
Vol 35 (1) ◽  
pp. 373-384
Author(s):  
YOSHIYUKI MIYAZAWA ◽  
YOSHITAKA SEKINE ◽  
SEIJI ARAI ◽  
DAISUKE OKA ◽  
HIROSHI NAKAYAMA ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Combined Androgen Blockade ◽  
Hormone Sensitive ◽  
Androgen Blockade

Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients

The Prostate ◽  
2020 ◽  
Vol 80 (11) ◽  
pp. 850-858
Author(s):  
Junryo Rii ◽  
Shinichi Sakamoto ◽  
Yasutaka Yamada ◽  
Nobushige Takeshita ◽  
Satoshi Yamamoto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
De Novo ◽  
Factors Influencing ◽  
Oligometastatic Prostate Cancer

scholarly journals 2SPD-033 Evaluation of docetaxel in low and high burden metastatic hormone sensitive prostate cancer

2021 ◽  
Author(s):  
MD Gil-Sierra ◽  
MDP Briceño-Casado ◽  
M Sanchez-Hidalgo ◽  
C Alarcon De La Lastra-Romero ◽  
B De La Calle-Riaguas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Burden ◽  
Hormone Sensitive

scholarly journals Oligometastatic Disease Detection with 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4982
Author(s):  
Carlos Artigas ◽  
Romain Diamand ◽  
Qaid Ahmed Shagera ◽  
Nicolas Plouznikoff ◽  
Fabrice Fokoue ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Predictive Factors ◽  
Clinical Management ◽  
Biochemical Recurrence ◽  
Oligometastatic Disease ◽  
Psma Pet ◽  
Pet Ct ◽  
Hormone Sensitive

Metastasis-directed therapy (MDT) in oligometastatic prostate cancer has the potential of delaying the start of androgen deprivation therapy (ADT) and disease progression. We aimed to analyze the efficacy of PSMA-PET/CT in detecting oligometastatic disease (OMD), to look for predictive factors of OMD, and to evaluate the impact of PSMA-PET/CT findings on clinical management. We retrospectively analyzed a homogeneous population of 196 hormone-sensitive prostate cancer patients (HSPC), considered potential candidates for MDT, with a PSMA-PET/CT performed at biochemical recurrence (BCR) after radical prostatectomy (RP). Multivariable logistic regression analysis was performed based on several clinico-pathological factors. Changes in clinical management before and after PSMA-PET/CT were analyzed. The OMD detection rate was 44% for a total positivity rate of 60%. PSMA-PET/CT positivity was independently related to PSA (OR (95%CI), p) (1.7 (1.3–2.3), p < 0.0001) and PSAdt (0.4 (0.2–0.8), p = 0.013), and OMD detection was independently related to PSA (1.6 (1.2–2.2), p = 0.001) and no previous salvage therapy (0.3 (0.1–0.9), p = 0.038). A treatment change was observed in 58% of patients, mostly to perform MDT after OMD detection (60% of changes). This study showed that PSMA-PET/CT is an excellent imaging technique to detect OMD early in HSPC patients with BCR after RP, changing therapeutic management mostly into MDT.

scholarly journals Integrated Analysis Revealed Prognostic Factors for Prostate Cancer Patients

2019 ◽  
Vol 25 ◽  
pp. 9991-10007
Author(s):  
Hong Che ◽  
Yi Liu ◽  
Meng Zhang ◽  
Jialin Meng ◽  
Xingliang Feng ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Integrated Analysis

scholarly journals 624P Prevalence and clinical impact of PTEN status in patients (pts) with de novo metastatic hormone sensitive prostate cancer (mHSPC)

2021 ◽  
Vol 32 ◽  
pp. S661
Author(s):  
J. Thouvenin ◽  
V. Colinet ◽  
P. Barthelemy ◽  
S. Sideris ◽  
M. Van Eycken ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
De Novo ◽  
Clinical Impact ◽  
Hormone Sensitive

scholarly journals Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients

2020 ◽  
Vol 10 ◽  
Author(s):  
Samantha S. Sigurdson ◽  
Francisco E. Vera-Badillo ◽  
Fabio Ynoe de Moraes
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Treatment Options ◽  
Hormone Sensitive

scholarly journals Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial

2020 ◽  
pp. 882-897 ◽  
Author(s):  
Clare Gilson ◽  
Fiona Ingleby ◽  
Duncan C. Gilbert ◽  
Marina A. Parry ◽  
Nafisah B. Atako ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Chromatin Remodeling ◽  
Metastatic Prostate Cancer ◽  
De Novo ◽  
High Volume ◽  
Pi3k Pathway ◽  
Mismatch Repair Gene ◽  
Copy Number Loss ◽  
Hormone Sensitive ◽  
Low Volume

PURPOSE The STAMPEDE trial recruits men with newly diagnosed, high-risk, hormone-sensitive prostate cancer. To ascertain the feasibility of targeted next-generation sequencing (tNGS) and the prevalence of baseline genomic aberrations, we sequenced tumor and germline DNA from patients with metastatic prostate cancer (mPCa) starting long-term androgen-deprivation therapy (ADT). METHODS In a 2-stage approach, archival, formalin-fixed, paraffin-embedded (FFPE) prostate tumor core biopsy samples were retrospectively subjected to 2 tNGS assays. Prospective enrollment enabled validation using tNGS in tumor and germline DNA. RESULTS In stage 1, tNGS data were obtained from 185 tumors from 287 patients (65%); 98% had de novo mPCa. We observed PI3K pathway aberrations in 43%, due to PTEN copy-number loss (34%) and/or activating mutations in PIK3 genes or AKT (18%) and TP53 mutation or loss in 33%. No androgen receptor ( AR) aberrations were detected; RB1 loss was observed in < 1%. In stage 2, 93 (92%) of 101 FFPE tumors (biopsy obtained within 8 months) were successfully sequenced prospectively. The prevalence of DNA damage repair (DDR) deficiency was 14% (somatic) and 5% (germline). BRCA2 mutations and mismatch repair gene mutations were exclusive to high-volume disease. Aberrant DDR (22% v 15%), Wnt pathway (16% v 4%), and chromatin remodeling (16% v 8%) were all more common in high-volume compared with low-volume disease, but the small numbers limited statistical comparisons. CONCLUSION Prospective genomic characterization is feasible using residual diagnostic tumor samples and reveals that the genomic landscapes of de novo high-volume mPCa and advanced metastatic prostate cancer have notable similarities (PI3K pathway, DDR, Wnt, chromatin remodeling) and differences ( AR, RB1). These results will inform the design and conduct of biomarker-directed trials in men with metastatic hormone-sensitive prostate cancer.

scholarly journals Evaluation of prognostic factors after radical prostatectomy in pT3b prostate cancer patients in Japanese population

2015 ◽  
Vol 45 (8) ◽  
pp. 780-784
Author(s):  
Takahiro Inoue ◽  
Hidefumi Kinoshita ◽  
Naoki Terada ◽  
Takashi Kobayashi ◽  
Toshinari Yamasaki ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Japanese Population
Sign in / Sign up

Export Citation Format

Share Document